Not a good buy right now for an impatient entry: price (5.94 pre-market) is pressing into near-term resistance (R1 ~6.04) with RSI elevated, making the risk/reward unfavorable without a catalyst.
Momentum is improving (MACD expanding), but the setup looks more like a late-stage push than an early entry; upside may be limited near 6.04–6.32 unless it cleanly breaks and holds.
Options positioning is extremely call-skewed and IV is extremely elevated (IV percentile 94), which reinforces “speculative” sentiment rather than a clean, low-risk equity entry.
Trend/momentum: MACD histogram is positive (0.0878) and expanding → bullish momentum is building.
RSI: RSI(6) at 72.86 → stretched/near-overbought conditions, often associated with short-term pullback risk.
Moving averages: converging MAs → trend is not strongly established; more prone to chop around key levels.
Key levels: Pivot 5.589 (important “line in the sand”); resistance at 6.04 (R1) then 6.318 (R2); support at 5.138 (S1) then 4.86 (S2).
Pattern-based probabilities: model suggests modest near-term upside (next day/week), but a negative bias over the next month (-3.98%), which argues against chasing strength.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Sentiment: Put/Call OI ratio 0.04 (calls dominate) → strongly bullish/speculative positioning.
Volatility: 30D IV ~432% with IV percentile 94 / IV rank 86.1 → options are priced for large moves; market is expecting (or paying for) big swings.
Liquidity/flow today: reported options volume is 0 → limited real-time confirmation of fresh demand today.
Takeaway: positioning looks bullish, but the extreme IV environment typically coincides with event-risk/speculation rather than a stable “easy” buy point for common shares.
Technical momentum is improving (positive, expanding MACD).
Analyst support: Evercore ISI Outperform with $13 PT (large upside vs. ~5.94), highlighting differentiated early-stage indications and supportive early data.
Neutral/Negative Catalysts
while sitting just below resistance (6.
→ higher odds of a near-term fade.
Financial Performance
Latest quarter: 2025/Q3.
Revenue: 0 (0.00% YoY) → still pre-commercial.
Net income: -$26.13M (improved 24.18% YoY) → losses narrowing, but still meaningfully negative.
Overall: improving loss profile on net income, but no revenue base yet; performance remains driven by pipeline progress rather than operating fundamentals.
Influential/political flows: No recent congress trading data available; insiders reported as neutral with no significant recent trend.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent analyst activity: Evercore ISI (2025-11-25) re-initiated at Outperform with a $13 price target, citing supportive early data and a differentiated approach in underserved early-stage indications.
Trend/changes: Only one recent data point provided; overall tone is bullish with a high implied upside.
Wall Street pros: differentiated mechanism/clinical angle; potential to open earlier-stage indications; strong PT vs. current price.
Wall Street cons: still pre-revenue; valuation and near-term price action likely driven by trial updates and sentiment, not fundamentals.
Wall Street analysts forecast AURA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AURA is 19.33 USD with a low forecast of 13 USD and a high forecast of 23 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast AURA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AURA is 19.33 USD with a low forecast of 13 USD and a high forecast of 23 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.360
Low
13
Averages
19.33
High
23
Current: 5.360
Low
13
Averages
19.33
High
23
Evercore ISI
Outperform
initiated
$13
AI Analysis
2025-11-25
Reason
Evercore ISI
Price Target
$13
AI Analysis
2025-11-25
initiated
Outperform
Reason
Evercore ISI re-initiated coverage of Aura Biosciences with an Outperform rating and $13 price target. Aura uses a photosensitive payload to kill tumor cells in a handful of "underserved," early-stage indications and early data has been "quite supportive," the analyst tells investors. The company's main target populations are earlier than the market is used to considering and with a safe and easy-to-give regimen, Aura could potentially open up these indications and avoid competition, the analyst added.
H.C. Wainwright
Andres Maldonado
initiated
$22
2025-05-28
Reason
H.C. Wainwright
Andres Maldonado
Price Target
$22
2025-05-28
initiated
Reason
H.C. Wainwright analyst Andres Maldonado assumed coverage of Aura Biosciences with a Buy rating and $22 price target. Aura is advancing a tumor-targeted platform that combines localized cytotoxicity with systemic immune activation, anchored by its proprietary virus-like drug conjugate technology, the analyst tells investors in a research note. The firm says the company is positioned to redefine the treatment paradigm in ocular oncology, where early intervention is often avoided due to the destructive nature of existing therapies.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for AURA
